Foquest in the Treatment of Attention Hyperactivity Deficit Disorder (ADHD) - With Case Study
ADHD is neurodevelopmental disorder affecting approximately 5.3% of the global population. Patients with ADHD exhibit extensive neurocognitive deficits that lead to impairments in working memory, reaction time, variability, vigilance, response inhibition, intelligence and achievement. Untreated ADHD patients are at a higher risk for social isolation, educational underachievement, lower socio-economic status, criminality, suicide, accidents, various addictions, and comorbid psychiatric disorders. Treatment options include neurotherapy, cognitive training, behavioral therapy and pharmacotherapy. Studies have shown that the stimulants, Methylphenidate (MPH) and Amphetamines, are the most beneficial pharmaceutical treatment options. MPH inhibits neuronal reuptake of dopamine and norepinephrine and reduces dopamine transport binding sites, thus normalizing neurocognitive networks in ADHD patients. Extended-Release treatments have been demonstrated to improve adherence. Foquest is a new MPH Hydrochloride, controlled-release, formulation with an onset of action within one hour and a duration of action of ≤ 16 hours. Health Canada approved Foquest for the treatment of adult ADHD in 2017, and extended approval to children and youth ≥ 6 years of age in March of 2019. In this article, we will explore the efficacy of Foquest as a new treatment option for ADHD patients. We will also present a case study that demonstrates improvement of psychosocial functioning and overall quality of life in an adult ADHD patient treated with Foquest.
Keywords - Attention Deficit Hyperactivity Disorder, ADHD, Methylphenidate, MPH, Foquest